Biocon Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended Dec. 31, 2018
January 24, 2019 at 12:46 pm
Share
Biocon Limited announced unaudited consolidated and standalone earnings results for the third quarter and nine months ended Dec. 31, 2018. For the quarter, on standalone basis, the company reported revenue from operations of INR 7,397 million compared with INR 5,921 million for the same period a year ago. Profit was INR 727 million compared with INR 437 million for the same period a year ago. Basic earnings per share (not annualized) were INR 1.23 against INR 0.74 a year ago. Diluted earnings per share (not annualized) were INR 1.22 against INR 0.74 a year ago.
For the nine months, on standalone basis, the company reported revenue from operations of INR 21,208 million compared with INR 17,774 million for the same period a year ago. Profit was INR 4,222 million compared with INR 1,666 million for the same period a year ago. Basic earnings per share (not annualized) were INR 7.14 against INR 2.83 a year ago. Diluted earnings per share (not annualized) were INR 7.09 against INR 2.81 a year ago.
For the quarter, on consolidated basis, the company reported revenue from operations of INR 15,408 million compared with INR 10,579 million for the same period a year ago. Profit was INR 2,172 million compared with INR 919 million for the same period a year ago. Basic earnings per share (not annualized) were INR 3.67 against INR 1.56 a year ago. Diluted earnings per share (not annualized) were INR 3.64 against INR 1.55 a year ago.
For the nine months, on consolidated basis, the company reported revenue from operations of INR 39,856 million compared with INR 29,602 million for the same period a year ago. Profit was INR 6,916 million compared with INR 2,420 million for the same period a year ago. Basic earnings per share (not annualized) were INR 11.69 against INR 4.10 a year ago. Diluted earnings per share (not annualized) were INR 11.61 against INR 4.08 a year ago.
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
BIOCON LIMITED 
